Table 7.

Lifetime Cost-Effectiveness Results for Base Case and Sensitivity Analyses

		Cost with CABG, $	Cost with PCI, $	Δ Cost ($) (95% CI)	QALYs with CABG	QALYs with PCI	ΔQALYs with CABG (95%CI)	ICER ($/QALY)	% Dominant	% Dominated	%< $50K
Tapered CABG Effect Between 5 and 10 Years	Base Case	114,571	109,179	5,392 (399, 10,320)	10.667	10.004	0.663 (0.177, 1.132)	8,132	1.5	0.4	99.2
	Lifetime analysis, Cost per Life Year Gained*	114,571	109,179	5,392 (399, 10,320)	12.177*	11.383*	0.794*	6,791*	1.5	0.2	99.7
	Lifetime analysis, Per Protocol population	114,855	108,878	5,976 (1,207, 10,925)	10.688	9.980	0.708 (0.202, 1.221)	8,440	0.7	0.2	99.3
	10 year time frame	81,710	80,295	1,416 (−2,061, 5,017)	6.684	6.455	0.230 (−0.008, 0.457)	6,156	22.8	1.7	95.8
	Lifetime analysis, no CABG effect on long term costs	121,244	109,179	12,045 (6,933, 17,103)	10.667	10.004	0.663 (0.177, 1.132)	18,167	0.0	0.5	97.4
Fixed CABG Effect Between 5 and 10 Years	Lifetime analysis	116,147	109,179	6,968 (1,273, 12,327)	10.867	10.004	0.864 (0.278, 1.426)	8,064	0.7	0.2	99.7
	10 year analysis	81,846	80,295	1,551 (−1,822, 5,292)	6.704	6.455	0.249 (0.016, 0.519)	6,229	18.8	1.4	96.7
No Effect of CABG after 5 Years	Lifetime analysis	118,664	109,179	9,485 (4,905, 13,995)	10.355	10.004	0.351 (−0.033, 0.713)	27,022	0.0	3.3	82.4
	10 year analysis	87,155	80,295	6,861 (3,408, 10,230)	6.541	6.455	0.086 (−0.088, 0.254)	79,779	0.0	17.8	27.0

^*Results presented in row 2 represent life years (columns 6–8) and cost per life year gained (column 9)

^**All costs, life-years, and QALYs discounted at 3% per year